ER-positive – Talk Bio

Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial

2 months ago talkbio0Tagged Adjuvant Therapy, Disease-Free Survival, ER-positive, giredestrant, HER2-negative, hormone receptor-positive, Hormone Therapy, Malignant neoplasm of breast, Oral SERD, phase III lidERA trial, Recurrence Risk, Roche (company), San Antonio Breast Cancer Symposium

Roche; giredestrant; breast cancer; hormone receptor-positive; ER-positive; HER2-negative; oral SERD; endocrine therapy; adjuvant therapy; recurrence risk; phase III lidERA trial; disease-free survival; San Antonio Breast Cancer Symposium

Roche’s Oral SERD Giredestrant Delays Early Breast Cancer Recurrence in Late-Stage Trial

2 months ago talkbio0Tagged Adjuvant Therapy, Disease-Free Survival, ER-positive, giredestrant, HER2-negative, Malignant neoplasm of breast, Oral SERD, Phase 3 trial, recurrence prevention, Roche (company)

Roche; oral SERD; giredestrant; Phase 3 trial; early breast cancer; ER-positive; HER2-negative; disease-free survival; adjuvant therapy; recurrence prevention

Roche Claims Its SERD Is Most Potent After Positive Breast Cancer Data Presented at ESMO 2025

3 months ago talkbio0Tagged ER-positive, giredestrant, HER2-negative, Malignant neoplasm of breast, Oral SERD, Phase 3 trial, Progression-Free Survival, Roche (company), Selective Estrogen Receptor Down Regulator

Roche; SERD; giredestrant; breast cancer; ESMO 2025; progression-free survival; oral SERD; ER-positive; HER2-negative; phase 3 trial

Roche’s Oral SERD Achieves Progression-Free Survival Milestone in Pivotal Breast Cancer Trial

4 months ago talkbio0Tagged advanced breast cancer, Clinical Research, ER-positive, giredestrant, Hormone Therapy, Malignant neoplasm of breast, Oral SERD, Phase 3 Clinical Trials, Progression-Free Survival, Roche (company)

Roche; oral SERD; giredestrant; progression-free survival; pivotal study; breast cancer; ER-positive; endocrine therapy; Phase III trial; advanced breast cancer

Olema Oncology Unveils Promising Data for Oral SERD Palazestrant Ahead of Phase III Trials

1 year ago talkbio0Tagged Antonio Breast Cancer Symposium, ER-positive, HER2-negative, Malignant neoplasm of breast, NAA50 gene, Olema Oncology, Oral SERD, palazestrant, Phase 3 Clinical Trials, SABCS

Olema Oncology, palazestrant, oral SERD, Phase III trials, breast cancer, ER-positive, HER2-negative, San Antonio Breast Cancer Symposium (SABCS)